Eli Lilly's Mounjaro Added to China's National Health Insurance Program
Eli Lilly and Company announced that its diabetes drug Mounjaro will be included in China's national health insurance reimbursement list starting January 1. This inclusion is expected to enhance the drug's accessibility to China's large population, though price reductions mandated by the reimbursement program may affect revenue. Mounjaro, launched in China earlier this year, competes with Novo Nordisk's Ozempic in the diabetic treatment market.